<DOC>
	<DOCNO>NCT02346578</DOCNO>
	<brief_summary>The objective study compare efficacy safety enzalutamide alternative AA therapy CRPC participants previously treat combine androgen blockade therapy include bicalutamide ( Bic-CAB ) . Efficacy safety enzalutamide alternative AA therapy evaluate , effective therapy CRPC treatment Bic-CAB investigate .</brief_summary>
	<brief_title>Comparative Study Alternative Antiandrogen ( AA ) Therapy Early Initiating Enzalutamide Castration-resistant Prostate Cancer ( CRPC ) After Combined Androgen Blockade ( CAB ) Therapy .</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<criteria>Testosterone le 50 ng/dL Participants detect disease progression image relapse PSA ( All PSA value measure 3 time least one week interval consecutively increase final value 2 ng/mL . If third value high second one , fourth measurement undertaken value must high second one . ) Participants relapse CAB bicalutamide Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Aged 20 year old Participants provide write informed consent Any prior treatment enzalutamide , flutamide , abiraterone chemotherapy , except neoadjuvant therapy With active double cancer Any prior treatment bicalutamide within 6 week Participants receive systemic biological therapy ( except exist approve drug bone treatment luteinizing hormonereleasing hormone ( LHRH ) analogue ) receive treatment antitumor agent prostate cancer With serious complication History hypersensitivity enzalutamide excipient enzalutamide History hypersensitivity flutamidecontaining agent With liver dysfunction Participants consider inadequate investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>